Advanced · 90D
1
Moved up a stage
Setbacks
1
Misses, holds, CRLs
Discontinued
2
Currently discontinued
Catalysts · 6 MO
8
Through Apr 11, 2027
Movement tracking since Oct 9, 2026. 90-day history covers 3 of 29 tracks shown; the rest are not counted as steady, because their history is not yet recorded.
Desk All Pharma Psychedelics Cannabis Digital
Modality All Drug + Therapy Device
Indication All indications Postpartum depression Major depressive disorder Treatment-resistant depression Major depressive disorder with insomnia symptoms Agitation associated with dementia due to Alzheimer's disease Alzheimer's disease psychosis Schizophrenia Schizophrenia, negative symptoms Attention-deficit/hyperactivity disorder Alcohol use disorder Generalized anxiety disorder Social anxiety disorder Post-traumatic stress disorder Insomnia Fragile X syndrome
Search program, generic name, sponsor or ticker
▲ Advanced in 90 days‖ Setback / holdDiscontinued Device and digital programs use FDA authorization stages: a 510(k) is cleared, not approved, though it sits in the last column.
PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILED APPROVED Serotonergic psychedelic 5-HT receptor agonists Entactogen Monoamine releasers NMDA modulator Ketamine class and related GABA-A modulator Neuroactive steroids κ-opioid antagonist Kappa-opioid receptor blockade Muscarinic M1/M4 Non-dopaminergic antipsychotics Orexin antagonist Sleep-linked depression Monoamine reuptake inhibitor Norepinephrine, dopamine, serotonin 5-HT2A antagonist Inverse agonists GIP / GLP-1 agonist Incretin-based Cannabinoid CBD and related Nasal chemosensory Neuroactive nasal sprays Neuromodulation & digital Devices and digital therapeutics AXS-05, AD agitation, Approved AXS-05 AD agitation AXS-05, MDD, Approved AXS-05 MDD BPL-003, TRD, Phase 3 BPL-003 TRD Brenipatide, AUD, Phase 3 Brenipatide AUD Brenipatide, MDD, Phase 3 Brenipatide MDD Centanafadine, ADHD, Approved Centanafadine ADHD Cobenfy, Schizophrenia, Approved Cobenfy Schizophrenia COMP360, TRD, Phase 3 COMP360 TRD CT-155, Schizophrenia, negative, Authorized (FDA cleared), advanced in the last 90 days CT-155 Schizophrenia, nega… · cleared ▲ DT120, GAD, Phase 3 DT120 GAD DT120, MDD, Phase 3 DT120 MDD Emraclidine, Schizophrenia, Phase 2 Emraclidine Schizophrenia Esketamine, TRD, Approved Esketamine TRD Fasedienol, SAD, Phase 3 Fasedienol SAD GH001, TRD, Phase 2 GH001 TRD HLP003, MDD, Phase 3 HLP003 MDD HLP004, GAD, Phase 2 HLP004 GAD Luvesilocin, PPD, Phase 2 Luvesilocin PPD MDMA-assisted therapy, PTSD, Phase 3 MDMA-assisted therapy PTSD Navacaprant, MDD, Phase 3, discontinued Navacaprant MDD × NBI-1117568, Schizophrenia, Phase 3 NBI-1117568 Schizophrenia Rejoyn, MDD, Authorized (FDA cleared) Rejoyn MDD · cleared Remlifanserin, AD psychosis, Phase 3, setback or on hold Remlifanserin AD psychosis ‖ Seltorexant, MDD + insomnia, Phase 3 Seltorexant MDD + insomnia Sleepio / Daylight, GAD, Authorized (FDA cleared) Sleepio / Daylight GAD · cleared Sleepio / Daylight, Insomnia, Authorized (FDA cleared) Sleepio / Daylight Insomnia · cleared TSND-201, PTSD, Phase 3 TSND-201 PTSD Usona psilocybin, MDD, Phase 3 Usona psilocybin MDD VLS-01, TRD, Phase 2 VLS-01 TRD Zuranolone, PPD, Approved Zuranolone PPD Zygel, Fragile X, Phase 3, discontinued Zygel Fragile X × Hover a program to trace it across indications; click for the full record. Movement tracking since Oct 9, 2026; 90-day history covers 3 of 29 tracks.
Last reviewed Oct 9, 2026. Each row carries its own verification date, shown in the program detail.